NasdaqGM:KIDS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has OrthoPediatrics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: KIDS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-9.0%

KIDS

-0.8%

US Medical Equipment

-1.5%

US Market


1 Year Return

8.9%

KIDS

15.2%

US Medical Equipment

12.9%

US Market

Return vs Industry: KIDS underperformed the US Medical Equipment industry which returned 15.2% over the past year.

Return vs Market: KIDS underperformed the US Market which returned 12.9% over the past year.


Shareholder returns

KIDSIndustryMarket
7 Day-9.0%-0.8%-1.5%
30 Day-24.7%1.2%-1.8%
90 Day-8.0%10.8%6.6%
1 Year8.9%8.9%16.2%15.2%15.4%12.9%
3 Yearn/a73.5%69.0%39.6%30.2%
5 Yearn/a158.1%138.5%93.4%71.7%

Price Volatility Vs. Market

How volatile is OrthoPediatrics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is OrthoPediatrics undervalued compared to its fair value and its price relative to the market?

3.32x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate KIDS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate KIDS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: KIDS is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: KIDS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KIDS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KIDS is good value based on its PB Ratio (3.3x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is OrthoPediatrics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

40.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KIDS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KIDS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KIDS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KIDS's revenue (27.6% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: KIDS's revenue (27.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if KIDS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has OrthoPediatrics performed over the past 5 years?

-2.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: KIDS is currently unprofitable.

Growing Profit Margin: KIDS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: KIDS is unprofitable, and losses have increased over the past 5 years at a rate of 2.5% per year.

Accelerating Growth: Unable to compare KIDS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KIDS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).


Return on Equity

High ROE: KIDS has a negative Return on Equity (-8.91%), as it is currently unprofitable.


Next Steps

Financial Health

How is OrthoPediatrics's financial position?


Financial Position Analysis

Short Term Liabilities: KIDS's short term assets ($180.4M) exceed its short term liabilities ($24.8M).

Long Term Liabilities: KIDS's short term assets ($180.4M) exceed its long term liabilities ($61.3M).


Debt to Equity History and Analysis

Debt Level: KIDS's debt to equity ratio (8.7%) is considered satisfactory.

Reducing Debt: KIDS's debt to equity ratio has reduced from 90.1% to 8.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KIDS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: KIDS has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 31.2% each year.


Next Steps

Dividend

What is OrthoPediatrics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate KIDS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KIDS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KIDS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KIDS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KIDS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.1yrs

Average management tenure


CEO

Mark Throdahl (69 yo)

9.67yrs

Tenure

US$1,190,153

Compensation

Mr. Mark C. Throdahl has been the Chief Executive Officer of OrthoPediatrics Corp. since January 2011 and had been its President since January 2011 until June 03, 2020. Mr. Throdahl has leadership experien ...


CEO Compensation Analysis

Compensation vs Market: Mark's total compensation ($USD1.19M) is below average for companies of similar size in the US market ($USD2.96M).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Mark Throdahl
CEO & Director9.67yrsUS$1.19m0.88%
$ 7.1m
David Bailey
President0.25yrUS$835.52k0.48%
$ 3.8m
Fred Hite
CFO, Principal Financial & Accounting Officer5.08yrsUS$1.00m0.35%
$ 2.8m
Daniel Gerritzen
VP of Legal & Human Resources11.67yrsUS$800.18k0.20%
$ 1.6m
Gregory Odle
Executive Vice President of Commercializationno dataUS$836.07k0.43%
$ 3.4m
Joel Batts
Senior Vice President of Science & Technology0.67yrno datano data
Peter Armstrong
Chief Medical Officer & Chair of Surgeon Advisory Boardno datano datano data
Joe Hauser
Senior VP & GM of Trauma & Deformity Correction0.67yrno datano data
Mark Karshner
Senior Vice President of International Sales4.67yrsno datano data

5.1yrs

Average Tenure

51yo

Average Age

Experienced Management: KIDS's management team is seasoned and experienced (5.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mark Throdahl
CEO & Director9.67yrsUS$1.19m0.88%
$ 7.1m
Fred Hite
CFO, Principal Financial & Accounting Officer5.08yrsUS$1.00m0.35%
$ 2.8m
Peter Armstrong
Chief Medical Officer & Chair of Surgeon Advisory Boardno datano datano data
Terry Schlotterback
Independent Chairman7yrsUS$83.79k0.098%
$ 787.8k
Bernie Berry
Independent Director11.67yrsUS$77.79k0.22%
$ 1.8m
Kevin Unger
Independent Director9.67yrsUS$77.79k0.021%
$ 172.8k
David Pelizzon
Director9.67yrsUS$77.79k0.088%
$ 707.8k
Bryan Hughes
Independent Director8.67yrsUS$80.79k0.026%
$ 205.9k
Henry Chambers
Member of Surgeon Advisory Boardno datano datano data
J. Gordon
Member of Surgeon Advisory Boardno datano datano data
H. Graham
Member of Surgeon Advisory Boardno datano datano data
Marie Infante
Independent Director6.67yrsUS$80.79k0.024%
$ 189.4k

9.2yrs

Average Tenure

64yo

Average Age

Experienced Board: KIDS's board of directors are considered experienced (9.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: KIDS insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 30.9%.


Top Shareholders

Company Information

OrthoPediatrics Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OrthoPediatrics Corp.
  • Ticker: KIDS
  • Exchange: NasdaqGM
  • Founded: 2007
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$804.450m
  • Shares outstanding: 19.55m
  • Website: https://www.orthopediatrics.com

Number of Employees


Location

  • OrthoPediatrics Corp.
  • 2850 Frontier Drive
  • Warsaw
  • Indiana
  • 46582
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KIDSNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDOct 2017
2X7DB (Deutsche Boerse AG)YesCommon StockDEEUROct 2017

Biography

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/22 06:17
End of Day Share Price2020/09/21 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.